Brief: Akebia Therapeutics Provides Update On Continued Momentum Of Commercial Launch Of Vafseo® (Vadadustat) Tablets

Akebia Therapeutics

11/07/2024 11:35

July 11 (Reuters) - Akebia Therapeutics Inc  AKBA.O :
    * AKEBIA THERAPEUTICS PROVIDES UPDATE ON CONTINUED MOMENTUM
OF
COMMERCIAL LAUNCH OF VAFSEO® (VADADUSTAT) TABLETS
    * AKEBIA THERAPEUTICS-AKEBIA REGAINS FULL RIGHTS TO SELL
VAFSEO
TABLETS IN U.S. FOLLOWING EXECUTION OF A ROYALTY-BASED
TERMINATION AGREEMENT WITH CSL
    * AKEBIA THERAPEUTICS INC: REGAINS FULL RIGHTS TO SELL
VAFSEO®
(VADADUSTAT) TABLETS IN U.S.
    * AKEBIA THERAPEUTICS INC -ANNOUNCED VAFSEO WAC PRICING OF
$1,278
FOR A 30-DAY SUPPLY
    * AKEBIA THERAPEUTICS INC: SUBMITTED TDAPA APPLICATION FOR
VAFSEO
IN JUNE 2024 AND EXPECTS DESIGNATION ON JANUARY 1, 2025

Source text for Eikon:  ID:nPn8mQjGRa 
Further company coverage:  AKBA.O 

 ((Reuters.Briefs@thomsonreuters.com;))